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Whole-blood sorting, enrichment and in situ immunolabeling
of cellular subsets using acoustic microstreaming
Neha Garg1, Trisha M. Westerhof2, Vick Liu3, Robin Liu4, Edward L. Nelson2,5,6 and Abraham P. Lee1,7,8
Analyzing undiluted whole human blood is a challenge due to its complex composition of hematopoietic cellular populations,
nucleic acids, metabolites, and proteins. We present a novel multi-functional microﬂuidic acoustic streaming platform that enables
sorting, enrichment and in situ identiﬁcation of cellular subsets from whole blood. This single device platform, based on lateral
cavity acoustic transducers (LCAT), enables (1) the sorting of undiluted donor whole blood into its cellular subsets (platelets, RBCs,
and WBCs), (2) the enrichment and retrieval of breast cancer cells (MCF-7) spiked in donor whole blood at rare cell relevant
concentrations (10 mL− 1), and (3) on-chip immunoﬂuorescent labeling for the detection of speciﬁc target cellular populations by
their known marker expression patterns. Our approach thus demonstrates a compact system that integrates upstream sample
processing with downstream separation/enrichment, to carry out multi-parametric cell analysis for blood-based diagnosis and
liquid biopsy blood sampling.
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INTRODUCTION
Efﬁcient separation of cellular populations from whole blood is an
essential preparatory step for many biological and clinical assays1.
Conventional macro-scale cell sorting techniques include density
gradient based centrifugation, immunolabeling-based separation
such as ﬂuorescence activated or, magnetic-activated cell sorting
(FACS, MACS, respectively) and CellSearch. However, these
techniques are limited by separation sensitivity, large blood
sample volume requirement, multi-step interventions prone to
artifacts, processing time, and cost. Lab-on-a-chip and microﬂuidic
systems developed for microscale separation techniques have
been gaining importance over the past decade. Many types of
unique cell sorting and enrichment devices have been devised but
they are not usually able to work with unprocessed whole
blood2–5. These technologies typically require pre-processed
samples and cannot handle the physical properties and complex
populations inherent in whole blood6–10. They are limited to
either diluted 11,12 or lysed blood13,14, and in some cases, density
based centrifugation to reduce blood complexity and cell-cell
interaction15–21.
The microﬂuidic cell sorting technologies that can handle
whole blood, in general fall into two categories: label free
sorting based on physical characteristics of the target cells or
biomarker labeling. For example, Davis et al.22 utilized
deterministic lateral displacement (DLD) to separate whole
blood components. Nagrath et al.23 used microposts and Stott
et al.24 utilized herringbone structures to capture EpCAM+ CTCs
from whole blood. In another study, Karabacack et al.25
integrated DLD with inertial focusing and magnetophoresis
for negative isolation of CTCs from whole blood. Although they
successfully demonstrated target cell sorting, they were unable
to enrich in a small volume (o50 μL).
Acoustic microstreaming has been demonstrated to focus, sort
and enrich target cells/particles within the microchannel26–32.
Studies have shown negligible adverse effect of ultrasonic
actuation on cellular phenotypes, viability and functional
capacity9,21,27,28,33,34. Acoustic microstreaming is a phenomenon
of localized streaming patterns occurring near an oscillating liquid
interface29. In lateral cavity acoustic transducers (LCATs), liquid–
gas interfaces are formed by trapped bubbles in patterned dead-
end side channels that form the acoustic microstreaming sources.
Oscillation of these bubble surfaces is actuated by an acoustic
energy source, leading to a second-order characteristic streaming
viscous ﬂow velocity, Us, which is maximum at the outer edge of
the microstreaming vortices. With the slanted LCAT angles, this
streaming ﬂow also induces a bulk ﬂow in the microchannel that
‘squeezes’ through an open streamline gap (termed dgap) that is
between the outer edge critical streamline of the vortex and the
oscillating liquid-air interface. Particles trapped in the vortices
form size-dependent orbits, where larger particles are pushed
towards vortex center (Figures 1a and c). Particles with radii
smaller than the dgap are released from the LCAT and are pumped
along with the bulk ﬂow. Therefore, LCATs are capable of bulk
pumping of the sample while simultaneously separating particles/
cells by size based on the bubble surface oscillation amplitude.
The oscillation thus controls the trapping and releasing of
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particles, correlated roughly to the ratio between bulk and
streaming velocities UbUS
 
(Refs. 28,30).
As depicted in Figure 1a, LCATs integrate the following sample
processing steps (1) separate whole blood into its cellular
constituents, (2) enrich rare cells based on size, and (3) deliver
ﬂuorescent biomolecules (monoclonal antibodies) to selectively
label target cells. These functions allow one to identify target cells
based on two important characteristics–size and surface biomar-
kers in a single device. Here we are utilizing enrichment ratio (ER,
materials and methods) as a metric to analyze the device
performance14,35,36. It is deﬁned as the enhancement of target
cell to background cell ratio from the device input to the output
sample36. ER in the order of ~ 100× to 1000 × is clinically
signiﬁcant for subsequent gene proﬁling by RT-PCR as discussed
by Tong et al.14,37 In our device, we enhanced the ER to 170× for
particle mixture (15 and 10 μm at initial ratio 1:1 00 000). We
achieved 213× enrichment of MCF-7 cells with respect to WBCs
when spiked at 10 mL− 1 in whole blood while ensuring the
capturing of all target cells and thus avoiding false negatives.
MATERIALS AND METHODS
Microﬂuidic device design
The LCAT chip is composed of 200 LCATs spaced 200 μm apart at an
angle of 15° relative to the main channel. The main channel width and
the side channel width were ﬁxed to 500 and 100 μm, respectively.
The height of the device was remained constant to 100 μm.
Microﬂuidic device fabrication
Microﬂuidic devices were fabricated using soft lithographic
techniques. Silicon wafer was ﬁrst cleaned with 2% HF to render
it hydrophobic and dehydrated at 120 °C for 15 min. Negative
photoresist, SU-8 2050 was spin coated per manufacturer’s
(Microchem) protocol for 100 μm height. Following spin coating,
it was soft-baked, exposed, post baked and developed. After hard
baking at 200 °C, it was kept in silane overnight. Poly (dimethylsi-
loxane), PDMS (Sylgard 184, Dow Corning) base and curing agent
at 11.5:1 ratio was mixed and poured on the mold. Following
degassing in a desiccator, it was cured at 65 °C overnight.
Hardened PDMS was cut and peeled carefully. Inlet hole was
punched with a 1.5 mm biopsy punch and the outlet was cut.
After cleaning the device, it was bonded on a thin cover slip
(Fisher Scientiﬁc) using standard plasma procedure (Harrick).
Following oxygen plasma, the bonded device was kept on a hot
plate set at 65 °C overnight to make the device hydrophobic.
MCF-7 cell culture
MCF-7 breast adenocarcinoma (HTB-185) cell line was procured
from ATCC (Manassas, VA, USA) and cultured per ATCC instruction
in DMEM (Mediatech, Manassas, VA, USA) supplemented with
fetal bovine serum (10%), penicillin (100U mL− 1), streptomycin
(100 g mL− 1) (Mediatech, Manassas, VA, USA), and Novolin R
insulin (44U L− 1) (Novo Nordisk, Plainsboro, NJ, USA).
SKBR-3 cell culture
SKBR-3 breast adenocarcinoma (HTB-30) cell line was procured
from ATCC (Manassas, VA, USA) and cultured as per ATCC
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Figure 1 Device schematics. (a) Schematic illustrating the size-based separation, enrichment and in situ labeling in the lateral cavity acoustic
transducer (LCAT) device. (b) Image of the polydimethylsiloxane (PDMS) based LCAT device. (c) Bright-ﬁeld image showing the trapping of
25 μm particles in the closed circular streamlines in comparison to the 10 μm particles in open streamlines.
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instructions in RPMI (Mediatech, Manassas, VA, USA) supplemen-
ted with fetal bovine serum (10%), penicillin (100U mL− 1), and
streptomycin (100 g mL− 1; Mediatech).
For biomarker staining on MCF-7 cells, anti-human EpCAM
CD326 antibody conjugated with PE-Dazzle 594 (Biolegend) was
used. After obtaining the cell pellet in an Eppendorf tube, they
were blocked by adding 60 μL staining buffer (1% BSA, 0.1% NaN3
in 1X PBS, pH 7.4) to re-suspend cell pellets with 20 μL of FcR block
(Miltenyi Biotech) for 10 min. Appropriate volumes of antibody
stain (3 μg mL− 1) was added and incubated for 30 min on ice.
Following incubation, the cells were washed with staining buffer
and collected by centrifugation at 1000 r.p.m. for 5 min. These pre-
stained cells were observed under ﬂuorescence and spiked in
whole blood at appropriate concentrations.
For nuclear staining of WBCs, we added DAPI (4',6-diamidino-2-
phenylindole) stain (Fisher Scientiﬁc) at the concentration of
1mg mL− 1 and incubated the sample for 10 min. Following that,
we imaged the stained cells using DAPI ﬁlter of the ﬂuorescent
microscope.
Blood sample collection and processing
Normal donor blood was obtained from Institution for Clinical
Translation and Science, UCI under Institutional Review Board (IRB)
approval. Whole blood with anti-coagulant was mixed with pre-
stained MCF-7 cells to represent target cancer cells/rare cells. All
normal donor blood was processed within 24 h after withdrawal.
The blood cells after separation were stained using Wright-Giemsa
Stain (Electron Microscopy Services). After making the smear of
whole blood and its separated components (RBCs and WBCs), the
cells were ﬁxed and stained using Wright-Giemsa stain for 5 min.
The glass slide is then washed in DI water carefully and dried for
observation under the microscope.
Microﬂuidic device experimental setup
The blood sample and 1× PBS buffer were supplied to the
microﬂuidic devices by 1 mL syringes connected to Harvard
Apparatus syringe pump and NE-500 (New Era), respectively. The
tubing of inner diameter 0.51 mm (Cole Parmer) was used to
connect the microﬂuidic device with the syringe. This tubing was
inserted in the inlet hole punch by a 1.5 mm biopsy punch and the
outlet was cut to ensure the release of 20 μL trapped sample. The
ultrasound gel (ultrasonic) was smeared on the piezoelectric
transducer (Steminc piezo) to ensure the efﬁcient transport of
acoustic wave from PZT to the PDMS device. The PZT was
connected to the function generator (Agilent 33220A) and the
voltage ampliﬁer (Krohn-Height 7500) to supply the square wave.
To monitor the functionality of the microﬂuidic device, we
connected a high-speed camera (Phantom, vision research) to a
L150 Nikon Eclipse upright microscope. Fluorescence detection
was performed using a 100 W, 488 nm laser for excitation and a
yellow green laser of 561 nm for detection by a canon DSLR
mounted on an Olympus IX 51 inverted microscope.
Enrichment Ratio :
ðTarget Cells=Background CellsÞoutput
ðTarget Cells=Background CellsÞinput
RESULTS
Isolation and separation of cells from whole healthy blood
The LCAT device (Figure 1b) was fabricated by soft lithography
techniques (materials and methods). To initiate the testing, the
device was ﬁrst primed with 1x PBS buffer to form air-liquid
interfaces, and then placed on a piezoelectric transducer (PZT)
with ultrasound gel. Undiluted normal donor whole blood (10 μL)
was then introduced into the inlet of the LCAT microchannel. The
mechanical vibration from the PZT (controlled by a function
generator) is coupled through the gel into the LCAT device to
actuate the air–liquid interfaces.
At 2Vpp, the PZT vibration induced the pumping of plasma and
small platelets in the blood, but RBCs and WBCs were trapped in
the vortices formed by the microstreaming ﬂow (Us). This resulted
in the collection of 2 μL of ﬂuid enriched for plasma and platelets
from the outlet. As the PZT voltage is increased to 2.5 Vpp, the
increase in Ub/Us results in RBCs being released from the
microstreaming vortices and collected from the outlet. To increase
the purity of separated sample, excess blood was pipetted out of
the inlet and replaced with 30 μL of PBS buffer. The device
remained driven at 2.5 Vpp, until all RBCs were ﬂushed out by the
buffer and WBCs remain trapped as shown in Supplementary
Video 1. After collecting all the RBCs from the outlet, the voltage
was further increased to 4.5 Vpp to release remaining trapped
WBCs. The separated samples were kept in individual vials for
inspection. The plasma and platelet sample was viewed in bright
ﬁeld at 40 × on a countess slide while the whole blood, and RBC
samples were stained with Wright-Giemsa stain to distinguish
them within (Figures 2a and b). WBC samples were spotted on a
ﬂuorescent microscope using DAPI nuclear stain (Figure 2b, right)
followed by the morphological analysis as shown in
Supplementary Figure S1. By utilizing imageJ software for
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Figure 2 Sample preparation of whole blood. (a) Smear of the whole
blood stained with Wright-Giemsa stain (left), 10 mL vial of whole
unprocessed blood. (b) Bright-ﬁeld image of vial containing plasma
containing platelets (left), Bright ﬁeld image of the smear of the RBC
sample after sorting from device (middle), Bright ﬁeld and
ﬂuorescent image (DAPI) of WBC sample after device operation
(right). (c) Bar graph showing the percent of cells in each sample
after sorting in device (n= 3).
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enumeration, the plasma sample consists of 96.3% platelets, the
RBC sample consists of 90.8% RBCs, and the WBC sample consists
of 66.4% WBCs (Figure 2c).
Integration of size-based separation with biomarker-based
immunolabeling
In some cases, rare cells such as circulating tumor cells or cancer-
associated ﬁbroblasts also exist in our circulatory system.
Separation and enrichment of these rare cells are of prime
interest for both prognosis and treatment monitoring. Post-
separation analysis such as identiﬁcation and enumeration can be
performed by immunoﬂuorescence and is unaffected by the
presence of non-target cells in the output sample. Currently,
despite considerable automation along with blood handling and
separation, detection by immuno-staining of target cells is
performed manually. The standard staining procedure takes at
least one hour, and requires expensive centrifuges to collect cells
maintained in suspension. To maximize the utility of lab-on-chip
devices in point-of-care setting, we have integrated size-based
separation with biomarker expression based immunolabeling. This
enables our device to integrate complete hematological separa-
tion of cellular subsets and on-chip immunoﬂuorescent labeling to
conﬁrm the identity of captured cells of interest based on both
size and biomarker, reducing turnaround time, minimizing labor-
intensive sample preparation, and limiting cost.
For proof of concept, MCF-7 breast cancer cells (2.1 × 105 mL− 1)
were prepared into a single cell suspension. The LCAT device
excitation voltage was set to capture the larger MCF-7 cells,
followed by on-chip staining with anti-human EpCAM mAb
conjugated to PE/Dazzle 594 (Biolegend). 30 μL of MCF-7 cell
suspension in PBS was pumped at 2.5 Vpp from the LCAT device
inlet for 5 min. After the cells were trapped in the microstreaming
vortices, 20 μL of Fc block (Miltenyi Biotec) was added in the inlet
after removing the extra cell sample. Fc block was ﬂown for 5min
followed by pumping 4 μL of CD326 (0.8 μg anti-EpCAM) antibody
for 2 min (2 μL min− 1). To prevent the inlet from emptying and air
entering the channel, 30 μL of staining buffer (1% BSA, 0.1% NaN3
in 1 × PBS, pH 7.4) was added to the inlet for 3 min. The buffer
also served to wash out any unbound antibodies in the channel.
After the cells were immunolabeled in the device, the ﬂuorescent
cells were imaged on-chip using a ﬂuorescent upright microscope
(Figure 3a). Subsequently, stained MCF-7 cells were released at
4.5–5 Vpp to analyze the ﬂuorescent intensity and the morphology.
We compared the detected expression level of the MCF-7 cells
stained using a standard benchtop procedure (0.8 μg, incubation
time of 50–60 min) to the 15 min in situ chip-based staining
procedure and a correlation of 91% demonstrates the similar
expression level detected via on-chip staining regardless of the
shortened staining time (Figure 3b).
After optimizing the immunostaining protocol, we sought to
produce a more realistic case by spiking MCF-7 cells into normal
donor whole blood samples (50 000 mL− 1). The spiked blood
samples were run through the device, with the intent to separate
the cancer cells from the blood. Platelets and RBCs were ﬁrst
extracted, followed by pumping of 30 μL of RBC lysing buffer
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Figure 3 In Situ labeling of MCF-7 cells from blood. (a) Fluorescent image of MCF-7 cells stained on device. Inset: bright-ﬁeld image of the
boxed region. (b) Plot of intensity correlation between staining protocol on device with benchtop staining (n= 3). (c) Fluorescent image of
MCF-7 cells after sorting, enriching, and on-chip labeling. (d) Bright-ﬁeld image of the released sample containing WBCs (smaller) and
MCF-7 cells.
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(Gibco) for 5 min to ensure complete removal of RBCs from the
microstreaming vortices. As a result, a mixture of remaining WBCs
and MCF-7 cells remained trapped at the microstreaming vortices.
At this point, we immunostained the MCF-7 cells with anti-EpCAM
antibody to discriminate them from the remaining WBCs on the
device using the protocol described above and released the
mixture at 4.5–5 Vpp. The released sample of 20μL was placed on a
countess slide, and imaged using a ﬂuorescent ﬁlter (Figure 3c), as
well as bright ﬁeld (Figure 3d). 10 × ratio increment (ER 9.71 × ) for
ﬂuorescently labeled MCF-7 cells with respect to WBCs conﬁrms
the identiﬁcation and enumeration of target cancer cells
speciﬁcally based on both size and marker expression, which is
particularly important for clinical blood samples.
Device optimization for analysis at rare concentration
At this point, we demonstrated a quick and portable technique for
separating blood components and detecting target cancer cells by
immunolabeling on a single device. While the size of circulating
tumor cells ranges from 15–25 μm, the rate of occurrence is 1–10
cells per mL of whole blood, thus making them extremely difﬁcult
to track38. Since rare cell detection requires a large sample volume
to process and to identify, enumerate and analyze, we used an
external syringe pump. The set-up in Figure 4a shows two syringe
pumps connected with a three-way valve for controlling the ﬂow
of undiluted blood sample and the wash buffer. The LCAT device
was primed with an aqueous solution of 10% glycerol in lipid to
maintain the stability of air-liquid interfaces and increase the time
of operation39. Due to an external bulk ﬂow, it was imperative to
optimize the device with respect to ﬂow rate and the voltage
applied to PZT.
As a model system, we evaluated the device sensitivity and
efﬁciency by utilizing polystyrene microparticles of varying sizes
that resembled cell diameters and concentrations of rare cells and
WBCs in whole blood. Fifteen micrometer particles were spiked at
10 000 particles per mL concentration in a solution containing one
million particles per mL of 10 μm particles. We obtained the
highest ER of 8.5 × at 25 μL min− 1 and 2.75 Vpp. At constant ﬂow
rate, Ub by the syringe pump, enrichment ratio reduces at larger
voltage values (reduced Ub/Us) due to non-speciﬁc trapping of
10 μm particles. However, at low voltage values (larger Ub/Us), due
to partial release of target 15 μm particles, a reduced ER was
observed (Figure 4b).
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showing pure vortices before (left) and after voltage switching (right). Plot of (d) trapping efﬁciency, and (e) enrichment ratio for 15 μm
particles at different concentrations in the presence of million per ml non-target 10 μm particles (n= 3).
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At 8.5 × ER, there was still non-speciﬁc trapping in the
microstreaming vortices. To increase the purity and ER, we
devised a voltage switching procedure by applying a short pulse
at low voltage while keeping bulk ﬂow at the same rate (Ub)
(Figure 1a). When Us decreases by reducing the PZT voltage to
2 Vpp, the increase in Ub/Us ratio allows 10 μm particles to be
released. To prevent 15 μm particles from releasing, this voltage is
maintained for only 30 s. After that, the ﬂow from the syringe
pump was switched off and the voltage was increased to 3.5 Vpp
for 1.5 min to remove 10 μm particles by the LCATs own ability of
generating bulk ﬂow. We removed 78.2% of non-target 10 μm
particles (Figure 4c), achieving 30 × ER from the same starting
material as above. To test at practical occurrence rate, we reduced
the spiking concentration of 15 μm particles to 10 mL− 1 and
achieved 170× ER with ~ 100% trapping efﬁciency (Figures 4d
and e).
Device validation with spiked particles and cultured cancer
cells from unprocessed blood
After validating the device with microparticle mixtures, the ability
to isolate particles from normal donor whole blood was tested. We
spiked 25 μm and 15 μm particles at concentrations ranging from
10 000 mL− 1 to 10 mL− 1. Flow for the spiked sample was
25 μL min− 1 and particles were trapped at 2.75Vpp. We imaged
the device using an upright microscope equipped with a high-
speed phantom camera, and observed at the beginning, the
channel ﬁlled with RBCs as shown in Figure 5a. After 14 min of
ﬂow, we switched the valve to introduce the wash buffer (1 × PBS)
at the same ﬂow rate for 20 min, with voltage switching to
maximize the release of non-target particles and achieve highly
pure vortices (Figures 5b and c).
One of the major requisites for the downstream processing
of target cells, such as genomic analysis, is the enrichment of
target cells in a small volume. Here after operating the device for
34min, the PZT was switched off and the trapped cells were
released in a 20 μL volume of buffer. We analyzed the original and
trapped sample on a countess slide using ﬂuorescent imaging as
shown in Figures 5d and e. At the higher concentration of
particles, 10 000 mL− 1 with WBCs at the original concentration of
one million cells per mL, the ER of the particles with respect to
WBCs was 70 × . We repeated the same procedure at low
concentrations and achieved 479× ER for 15 μm particles and
531× for 25 μm particles at 10 mL− 1 spiking concentration
(Figure 5f).
As a ﬁnal proof-of-concept experiment, the separation and
enrichment of MCF-7 breast cancer cells from whole blood was
demonstrated. MCF-7 cancer cells in suspension were immuno-
ﬂuorescently stained with anti-EpCAM antibody and then spiked
into normal donor whole blood at concentrations ranging from
1,000 mL− 1 to 10 mL− 1. The trapping and enrichment of MCF-7
cells was performed using the same protocol described in the
sections above. After processing 400 μL of spiked blood sample
(separately spiked with 25 μm, 15 μm and MCF-7 cells) for 34min,
we could capture and image 3–4 particles (Figures 6a and b) and 4
cells (Figure 6c) when they were spiked at initial concentration of
10 mL− 1 in whole blood, thereby giving ~ 100% trapping
efﬁciency (Figure 6e). After counting the ﬂuorescent MCF-7 cells
in the ﬁnal sample, we obtained 213× enrichment at 10 mL− 1
spiking concentration (Figure 6f). In addition, we cultured the
enriched MCF-7 and SKBR-3 cells for 3 days in conditioned media
to ensure the preservation of phenotypic and genotypic
characteristics after ultrasound exposure and obtained successful
proliferation after acoustic exposure as shown in bright ﬁeld
images (Figure 6d). We immunostained MCF-7 and SKBR-3 cells in
culture with DAPI antibody and obtained multiple nuclei as shown
in Figure 6d (right). We further stained MCF-7 cells with anti-
EpCAM antibody and observed intact cell membranes as shown in
Supplementary Figure S2.
DISCUSSION
Rare cells in the circulatory system carry signiﬁcance for improving
cancer prognosis and monitoring treatment response1. The
ultimate goal of liquid biopsy based detection of rare cells
requires a multi-modal system that can process raw samples by
separating, sorting and enriching for speciﬁc cell populations, and
ﬁnally identifying the targeted cells via known biological
markers40. Typically, each of these processes require separate
instruments and the transfer of samples across different platforms,
resulting in lowered sensitivity, speciﬁcity, and added costs. As
described in this paper, our LCAT rare cell isolation platform can
process whole blood without dilution, separate out the cellular
subcomponents, isolate and enrich the targeted size-based
population, and perform in situ immunolabeling. There is no
other liquid biopsy system that can achieve this level of
integration and multi-modal functionality. For example, the ﬁrst
category of rare cell detection platforms relied on surface
biomarkers (for example, EpCAM) and the binding to antibody-
coated surfaces to ﬁlter and concentrate rare cells such as CTCs.
However, it is now well known that cancer cells can undergo
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(a) Bright-ﬁeld image of whole spiked blood in the LCAT device. (b)
Bright-ﬁeld image during the washing step in the device. (c) Bright-
ﬁeld image of pure vortices with 25 μm particles trapped after the
device operation. (d) Fluorescent image of initial spiked blood (with
25 μm particles) at 10 000 per mL concentration. (e) Fluorescent
image of enriched 25 μm particles after releasing from device. (f)
Plot of enrichment ratio with varying spiking concentration of 25
and 15 μm diameter particles; (n= 3) for each spiking concentration.
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epithelial to mesenchymal transition (EMT) in circulation, causing
undesired false negatives41. Another promising category of
microﬂuidic systems is “label-free”, and they are able to sort
blood cells based on their sizes using known techniques such
as deterministic lateral displacement (DLD)22,42, inertial
microﬂuidics43, and acoustophoresis20,21,44. However, recent
developments in oncology have shown heterogeneity and great
size overlap between rare cells such as CTCs and healthy
WBCs19,45. Being able to separate blood cell sub-populations with
ﬁne resolution to deﬁne a size threshold that ensures ~ 100%
capture of targeted rare cells, and then identify the targeted cells
within this concentrated population via gentle immunolabeling
in situ is a powerful combination of techniques needed for liquid
biopsy. An integrated system that is multimodal, label-free,
biomarker compatible, low cost and can be fully automated has
enormous potential to make clinical impact. In this paper, our
device has demonstrated the enrichment of MCF-7 cells
from whole blood at concentrations as low as 10 mL− 1, at
~ 100% capture efﬁciency, and veriﬁed by EpCAM biomarker
staining in situ. In contrast, although hydrodynamic vortices based
devices demonstrated cancer cell enrichment up to four orders of
magnitude, it required signiﬁcant blood dilution to avoid cell-cell
interactions and the capture efﬁciency was only ~ 20%11. Another
enormous advantage of this LCAT platform is in the speed of
operation for cell enrichment and identiﬁcation. Considering just
the downstream analysis and enumeration of target cells after
enrichment, benchtop immunostaining and ﬁxation could take
several hours. However, to develop an inexpensive and automated
point-of-care device, we labelled the captured target cells in situ
within 15 min and achieved 91% correlation in the ﬂuorescence
intensity by optimizing the LCAT pumped bulk ﬂow.
While our system has great potential for liquid biopsy, it may be
limited by throughput due to the low ﬂow rate and the instability of
LCATs over time. Inertial microﬂuidics based devices are high-
throughput (mL min−1) but require signiﬁcant dilution. Our strategy
to improve throughput is to parallelize LCAT devices and increase the
total blood sample volume it can handle. We are also optimizing the
length of the sorting microchannels to maximize microﬂuidic
channel length while minimizing hydrodynamic resistance. Another
possibility is to ﬂow a second pass of the enriched 20 μL sample in
the device to reduce the volume required in the ﬁrst place since it is
likely the enrichment ratio will be greatly improved.
Overall, this work demonstrates a highly promising approach
for integrated isolation, enrichment, release and identiﬁcation of
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Figure 6 Enrichment of 25 μm, 15 μm and MCF-7 cells in whole blood. Fluorescent image of (a) 25 μm, (b) 15 μm and (c) MCF-7 cells released
after analyzing 400 μL of whole blood sample in device at 10 mL− 1 spiking level. (d) Bright ﬁeld and ﬂuorescent image (DAPI) showing the
MCF-7 (top) and SKBR-3 cells (bottom) proliferating on the culture plate. (e) Plot of the trapping efﬁciency for 25 μm, 15 μm diameter particles
and MCF-7 cells at 100 mL− 1 and 10 mL− 1 concentration in whole blood (n= 3). (f) Plot of enrichment ratio with varying concentration of
MCF-7 cells in whole unprocessed blood sample (n= 3).
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targeted blood cells, and ultimately could lead to the develop-
ment of complete point-of-care blood diagnosis. The technology,
based on acoustic microstreaming, processes whole blood and
does not require centrifugation or benchside processing of
separated blood components. Thus, an offshoot of this technology
is to create a complete blood sample preparation front end device
able to separate each of the blood cellular component (platelets,
RBC and WBC), as each of these components contain critical
information for the diagnosis of physiologic and pathologic
conditions such as infectious diseases and inﬂammatory
responses.
CONCLUSIONS
An acoustic microstreaming based LCAT device that can process
whole blood and all its cellular constituents by size-based sorting,
enrichment and subsequent biomarker-based identiﬁcation is
reported. This is, to our knowledge, the ﬁrst demonstration of a
single microﬂuidic device that combines the advantages of both
label-free detection and in situ immunolabeling to select for
targeted speciﬁc cell types. It is also the ﬁrst device that can
separate and collect the major components in whole blood
(platelet rich plasma sample, RBCs and WBCs). Rapid immunola-
beling (15 min) was demonstrated as targeted cells were trapped
in microstreaming vortices. With these novel integrated functions,
we demonstrated ~ 100% trapping efﬁciency of spiked polystyr-
ene beads and MCF-7 cells in whole blood and achieved ~ 200×
enrichment ratio in the sorted sample of 20 μL for concentrations
as low as 10 mL− 1.
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